How to Help Your Patients Save Money on Octreotide: A Provider's Guide to Savings Programs

How to Help Your Patients Save Money on Octreotide

For patients on Octreotide, cost is more than an inconvenience — it's a barrier to adherence. When a medication costs anywhere from $3,000 to $10,000 per month depending on the formulation, even patients with insurance can face significant out-of-pocket burden. Patients without adequate coverage may skip doses, delay refills, or abandon treatment altogether.

As a prescriber, you're uniquely positioned to intervene before cost becomes a clinical problem. This guide covers the savings programs, generic options, and workflow strategies that can make Octreotide more accessible for your patients.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you anticipate where patients will hit barriers:

• Generic immediate-release injection: $40–$110 for 10 vials (100 mcg/mL) with a coupon — the most affordable option, available from Avet, Fresenius Kabi, Hikma, and Sagent
• Generic LAR (Teva): $3,000–$5,500 per monthly injection — approved October 2024, offering meaningful savings over brand
• Sandostatin LAR Depot (Novartis brand): $6,700–$8,500 per monthly injection
• Mycapssa oral capsules (Amryt): $8,000–$10,000 per month

For commercially insured patients, copays on specialty tiers can range from $100 to $500+ per month even with coverage. Medicare Part B patients may face 20% coinsurance on physician-administered LAR injections. Uninsured patients face the full cash price.

The gap between "covered" and "affordable" is where most patients struggle — and where your guidance matters most.

Manufacturer Savings Programs

Novartis Patient Support (Sandostatin LAR Depot)

Novartis offers a copay assistance card for commercially insured patients on Sandostatin LAR Depot, providing up to $15,000 per calendar year in copay assistance. This can eliminate or significantly reduce monthly copays for many patients.

Key details:

• Available to commercially insured patients only (not Medicare, Medicaid, or other government programs)
• Patients can enroll at the Novartis patient support website or by calling the Sandostatin support line
• The card typically applies automatically at the specialty pharmacy

Novartis Patient Assistance Foundation

For uninsured or underinsured patients who meet income criteria, the Novartis Patient Assistance Foundation provides Sandostatin at no cost. This is one of the most robust manufacturer PAPs in the specialty space.

Eligibility:

• No insurance or inadequate coverage for Sandostatin
• Income below program thresholds (typically 400-500% of federal poverty level)
• U.S. resident with valid prescription

Your office will need to complete a brief enrollment form and provide a prescription. Turnaround is typically 1–2 weeks for initial approval.

Amryt Patient Support (Mycapssa)

Amryt Pharma offers patient support programs for Mycapssa, including copay assistance and access support. Given the $8,000–$10,000 monthly cost, this support is essential for any patient transitioning to oral Octreotide.

Independent Copay Foundations

Several independent foundations provide copay assistance for patients with neuroendocrine tumors, acromegaly, and related conditions:

• PAN Foundation — Offers copay assistance for neuroendocrine tumor patients. Fund availability fluctuates, so encourage patients to apply early and check periodically if waitlisted.
• HealthWell Foundation — May offer assistance for acromegaly or neuroendocrine tumor patients depending on fund status.
• NeedyMeds (needymeds.org) — Comprehensive database of patient assistance programs, discount cards, and state-specific resources.
• RxAssist (rxassist.org) — Patient assistance program directory maintained by Volunteers in Health Care.

These foundations typically help with copays and coinsurance for insured patients. Eligibility is usually based on income, diagnosis, and insurance status.

Coupon and Discount Cards

For patients paying cash for generic immediate-release Octreotide injection, discount cards can reduce costs further:

• GoodRx — Often shows generic Octreotide injection at $40–$80 for 10 vials at retail pharmacies
• SingleCare — Comparable savings on generic formulations
• RxSaver — Price comparison across local pharmacies

Important caveat: These cards are most useful for the relatively affordable generic immediate-release injection. They do not meaningfully reduce the cost of LAR formulations or Mycapssa, which are typically $3,000+ per month and dispensed through specialty pharmacies.

For a comprehensive patient-facing guide, refer patients to our post on how to save money on Octreotide.

Generic Alternatives and Therapeutic Substitution

Generic Octreotide Options

The generic landscape has improved significantly:

• Generic immediate-release injection: Available from multiple manufacturers (Avet, Fresenius Kabi, Hikma, Sagent) — well-established and affordable
• Generic LAR (Teva): Approved October 2024. Priced at $3,000–$5,500 per month vs. $6,700–$8,500 for brand Sandostatin LAR. This represents potential savings of $2,000–$4,000 per month for patients who can switch.

When insurance requires step therapy, starting with generic immediate-release Octreotide satisfies this requirement while keeping costs low during the stabilization period.

Therapeutic Alternatives

If Octreotide is cost-prohibitive or unavailable, consider these therapeutic alternatives based on indication:

• Lanreotide (Somatuline Depot): Similar efficacy for acromegaly and GEP-NETs. Check whether your patient's plan has a lower tier for Lanreotide — formulary placement varies between plans.
• Pasireotide (Signifor/Signifor LAR): Second-generation somatostatin analog for patients inadequately controlled on first-generation agents. Higher hyperglycemia risk. Typically more expensive.
• Pegvisomant (Somavert): GH receptor antagonist for acromegaly. Different mechanism — useful when somatostatin analogs are insufficient. Also high-cost.
• Telotristat Ethyl (Xermelo): Add-on for carcinoid syndrome diarrhea not controlled by somatostatin analogs. Not a substitute but may allow dose optimization.

For a detailed comparison, see our post on alternatives to Octreotide.

Building Cost Conversations Into Your Workflow

The most effective cost intervention is the one that happens before the patient leaves your office with a prescription they can't afford. Here are practical workflow strategies:

Screen for Cost Barriers at Every Visit

A simple question works: "Are you having any difficulty affording your Octreotide?" Patients often won't volunteer this information — they'll just skip doses quietly. Asking directly gives permission to discuss it.

Know Your Specialty Pharmacy Contacts

Your specialty pharmacy representatives can check benefits, estimate copays, and initiate prior authorizations before the patient fills. Building a relationship with 1–2 specialty pharmacies that handle Octreotide well saves everyone time.

Front-Load the Prior Authorization

Don't let PA denials create treatment gaps. Submit prior authorization before switching formulations and keep documentation ready:

• Diagnosis with supporting labs/imaging
• Trial-and-failure documentation if step therapy applies
• Medical necessity letter for preferred formulation

Prescribe Generic When Appropriate

With Teva's generic LAR now available, explicitly prescribing generic Octreotide LAR (rather than brand Sandostatin LAR) can save patients thousands per month. Make sure your prescription allows generic substitution unless there's a clinical reason to require brand.

Connect Patients With Resources

Consider creating a handout or resource sheet for your Octreotide patients that includes:

• Novartis patient support phone number
• PAN Foundation and HealthWell Foundation application links
• NeedyMeds and RxAssist websites
• Link to Medfinder for Providers for pharmacy stock lookup

Having this ready to hand patients at the point of prescribing eliminates the most common barrier: patients not knowing where to look for help.

Monitor for Shortage-Related Cost Spikes

When Octreotide formulations go on shortage, some patients may be pushed to more expensive alternatives or out-of-network pharmacies. Stay aware of current availability through the FDA Drug Shortage Database and Medfinder's provider tools.

Final Thoughts

Octreotide is a clinically essential medication for your patients with acromegaly, carcinoid syndrome, and neuroendocrine tumors. But at $3,000 to $10,000 per month, the financial burden is real — and it directly impacts adherence and outcomes.

The tools exist to make Octreotide more affordable: manufacturer programs, generic alternatives, foundation copay assistance, and proactive prescribing strategies. The key is building cost awareness into your clinical workflow so that savings conversations happen before patients face a crisis at the pharmacy counter.

For real-time pharmacy availability and stock checking, Medfinder for Providers can help you and your patients locate Octreotide quickly when it matters most.